A new nanodrug for treating metabolic diseases
Official title: A Novel Nanodrug for Metabolic Disease Treatment
Funded at University of California at Davis · NIH-11171208 · Data updated 2026-11-12
This study is testing a new oral medication designed to help people with type 2 diabetes and reduce the risk of liver and colorectal cancers by improving gut health, and it has shown promising results in mice.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | September 2, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $594,547 |
| NIH project number | 1R56DK140492-01 |
| Project ID | NIH-11171208 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults suffering from metabolic diseases such as type 2 diabetes or those at risk for liver and colorectal cancers.
✕Less likely to help
Patients who do not have metabolic diseases or related conditions may not benefit from this research.
What this research studies
This research focuses on developing a novel nanodrug aimed at treating metabolic diseases such as type 2 diabetes and conditions that can lead to liver and colorectal cancers. The approach involves creating an orally delivered drug that targets gut dysbiosis, which is linked to metabolic dysfunction. By utilizing advanced drug synthesis techniques, the researchers aim to enhance the signaling pathways that are often disrupted in patients with these conditions. The effectiveness of this drug has been tested in mouse models, showing promising results in improving metabolic health.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that improves metabolic health and reduces the risk of cancer in affected patients.
How similar studies have gone: Previous research has shown success in using similar approaches to target gut dysbiosis for metabolic disease treatment, indicating potential for this novel drug.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Wan, Yu-Jui Yvonne — University of California at Davis
- Study coordinator: Wan, Yu-Jui Yvonne
Related research
Other NIH-funded projects on the same topics.
-
Dysfunctional fat tissue and its link to fatty liver and diabetes
Researchers are studying how problems in fat tissue contribute to fatty liver disease and type 2 diabetes in adults.
-
Role of the body's natural cannabis-like system in diabetes progression and heart risk
This grant studies how the body's endocannabinoid system affects the progression from obesity to diabetes and the associated risk for cardiovascular disease in adults.
-
Exploring vagal gut-brain signals to treat obesity
Researchers are studying how the vagus nerve communicates about eating to see if targeting gut-brain signals can help treat obesity.
-
Early-life sodium loss and brain signals that shape long-term heart and metabolism health
This project studies how losing sodium in early life can set the brain’s pressure and salt-checking system to influence heart and metabolic health later on.
-
Role of gut bacteria–driven Th17 cells in metabolic health
A study in mice explores how specific gut bacteria help protect against obesity- and diabetes-like changes by shaping a type of immune cell in the gut.
-
Genetics of chronotype and its links to metabolic disease
Researchers are studying how a person’s natural daily rhythm and sleep timing influence the risk for adult-onset diabetes and related metabolic problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.